A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 93
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : H2RAs
Long Form : H2-receptor antagonists
No. Year Title Co-occurring Abbreviation
2020 Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients. CP-CML, PPIs
2020 Practice patterns of reflux medication prescriptions in otolaryngology compared to other specialties. PPI
2019 Early Acid Suppression Therapy Exposure and Fracture in Young Children. AST, PPIs
2019 Omeprazole prevents CDX2 and SOX9 expression by inhibiting hedgehog signaling in Barrett's esophagus cells. BE, Hh, PPIs
2019 The Reduction in Gastric Atrophy after Helicobacter pylori Eradication Is Reduced by Treatment with Inhibitors of Gastric Acid Secretion. H. pylori
2019 Use of Acid-Suppressant Medications After Diagnosis Increases Mortality in a Subset of Gastrointestinal Cancer Patients. HCCs, HRs, PPIs
2018 Long-term use of proton pump inhibitors, dose-response relationship and associated risk of ischemic stroke and myocardial infarction. CI, HR, MI, PPIs
2018 Potent Acid Suppression with PPIs and P-CABs: What's New? DR-PPIs, GERD, H. pylori, IR-omeprazole, MR, NSAID, PPIs, UGI
2018 Proton Pump Inhibitors, H2-Receptor Antagonists, Metformin, and Vitamin B-12 Deficiency: Clinical Implications. PPIs
10  2018 Use of histamine H2 receptor antagonists and outcomes in patients with heart failure: a nationwide population-based cohort study. HRs, PPIs
11  2017 Association Between Proton Pump Inhibitor Use and Cognitive Function in Women. PPI
12  2017 Associations of Acid Suppressive Therapy With Cardiac Mortality in Heart Failure Patients. PPIs
13  2017 Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis. CI, CKD, PPIs, RR
14  2017 Prospective Study of Gastroesophageal Reflux, Use of Proton Pump Inhibitors and H2-Receptor Antagonists, and Risk of Hearing Loss. GERD, PPIs
15  2017 Proton pump inhibitors for functional dyspepsia. CI, NNTB, PPIs, RCTs, RR
16  2017 Proton pump inhibitors for functional dyspepsia. CI, NNTB, PPIs, RCTs, RR
17  2017 Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin. CI, GI, PPI
18  2017 The Effect of H2 Receptor Antagonist in Acid Inhibition and Its Clinical Efficacy. GERD, PPIs
19  2016 Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. EGFR, NSCLC, OS, PFS, PPIs
20  2016 Are proton pump inhibitors really so dangerous? PPI
21  2016 The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies. CI, GIB, NOACs, PPIs, RR
22  2015 PPI versus Histamine H2 Receptor Antagonists for Prevention of Upper Gastrointestinal Injury Associated with Low-Dose Aspirin: Systematic Review and Meta-analysis. CI, GI, LDA, PPIs
23  2015 The changing patterns of dispensing branded and generic drugs for the treatment of gastroesophageal reflux disease between 2006 and 2011 in Japan: a retrospective cohort study. GERD, PPIs
24  2015 Toward More GI-Friendly Anti-Inflammatory Medications. COX, NSAIDs, PPIs
25  2015 [Coverage of diagnostic upper gastrointestinal endoscopy for the prevention of gastric cancer in Chile: results from the 2009-2010 National Health Survey]. GC, PPIs, PUGB, UGE
26  2014 Comparison of teprenone and famotidine against gastroduodenal mucosal damage in patients taking low-dose aspirin. GPs, LDA
27  2014 Difference in risk of gastrointestinal complications between users of enteric-coated and buffered low-dose aspirin. ASRs, GI, LDA, PPIs
28  2014 [Prophylaxis for stress ulcer bleeding in the intensive care unit]. PPIs
29  2013 Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists. PPIs, SUB, VAP
30  2013 Difference between the frequencies of antisecretory drug prescriptions in users of buffered vs. enteric-coated low-dose aspirin therapies. GI, LDA, PPIs
31  2013 Differences in utilisation of gastroprotective drugs between 2001 and 2005 in Australia and Nova Scotia, Canada. AUS, NS, PPIs
32  2013 Gastroesophageal reflux in pregnancy: a systematic review on the benefit of raft forming agents. GERD, PPIs
33  2012 Exacerbation of nonsteroidal anti-inflammatory drug-induced small intestinal lesions by antisecretory drugs in rats: the role of intestinal motility. NSAIDs, PPIs
34  2011 Clinically significant drug interactions with antacids: an update. DDIs, OTC, PPIs
35  2011 The effects of nizatidine on transient lower esophageal sphincter relaxations (TLESRs) and acid reflux in healthy subjects. EAE, NIZ, RE, TLESRs
36  2011 Use of selective serotonin reuptake inhibitors and upper gastrointestinal disease. PPIs, SSRIs
37  2011 WITHDRAWN: Medical treatments in the short term management of reflux oesophagitis. PPIs
38  2010 The rate of prescribing gastrointestinal prophylaxis with either a proton pump inhibitor or an H2-receptor antagonist in Nova Scotia seniors starting nonsteroidal anti-inflammatory drug therapy. GI, GPA, NSAIDs, PPI
39  2009 Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough. CENTRAL, NAB
40  2009 Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. COX-2s, GI, PPIs, RCTs, tNSAIDs
41  2009 Proton pump inhibitor use and enteric infections. PPIs
42  2009 WITHDRAWN: Initial management strategies for dyspepsia. CI, GORD, H. pylori, PPI, PPIs, RR
43  2008 Acid-suppressive medications and risk of bone loss and fracture in older adults. BMD, CI, PPIs, RH, SOF
44  2008 Four-day continuous gastric pH monitoring following anti-acid secretory drug administration: cross-over test to assess the early effects. PPIs
45  2007 Does long-term medication with a proton pump inhibitor induce a tolerance to H2 receptor antagonist? PPIs
46  2007 Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial. EGC, ESD, PPIs
47  2007 Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. CI, COX-2, GI, NSAID, PPIs, RR, UGIB
48  2007 Medical treatments in the short term management of reflux oesophagitis. PPIs
49  2007 Prescription of nonsteroidal anti-inflammatory drugs and co-prescribed drugs for mucosal protection: analysis of the present status based on questionnaires obtained from orthopedists in Japan. NSAIDs, PAs, PPIs
50  2007 [Acid-suppressive strategy against gastroesophageal reflux diseases and non-erosive reflux diseases: the alternative of proton- pump inhibitors or H2 receptor antagonists]. ERD, GERD, H. pylori, NERD, PPIs
51  2006 Patients' views on dyspepsia and acid suppressant drug therapy in general practice. ASD, PPIs
52  2006 What is the best way to manage GERD symptoms in the elderly? GERD, PPIs, RCTs, SOR, SOR, SOR
53  2005 "Proton-pump inhibitor-first" strategy versus "step-up" strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan. GERD, PPIs
54  2005 Development and validation of the Gastroesophageal Reflux Disease Treatment Satisfaction Questionnaire. GERD, GSAS, PPIs
55  2005 Dose-reducing H2 receptor antagonists in the presence of low glomerular filtration rate: a systematic review of the evidence. AUC, GFR
56  2005 Evidence-based recommendations for short- and long-term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool. CanDys, UD
57  2005 Initial management strategies for dyspepsia. CI, GORD, H. pylori, PPI, PPIs, RR
58  2005 One-week versus two-week H2-receptor antagonist in combination with amoxicillin and tinidazole for eradication of Helicobacter pylori infection. H. pylori
59  2005 Overview of pharmacologic agents for acid suppression in critically ill patients. PPIs
60  2005 Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta-analyses. PPIs
61  2005 Science review: The use of proton pump inhibitors for gastric acid suppression in critical illness. ICUs, PPIs, SRMD
62  2004 Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough. CENTRAL, NAB
63  2003 Optimizing medical therapy for gastroesophageal reflux disease: state of the art. PPIs
64  2003 The influence of feeding on gastric acid suppression in Helicobacter pylori-positive patients treated with a proton pump inhibitor or an H2-receptor antagonist after bleeding from a gastric ulcer. PPI, PPIs
65  2003 Therapeutic approaches to reflux disease, focusing on acid secretion. GERD, PPIs
66  2001 A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis. GI, GPAs, NSAIDs, PPIs
67  2000 A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. GERD, PPIs, QALYs
68  2000 H2-receptor antagonists may increase the risk of cardio-oesophageal adenocarcinoma: a case-control study. COA, DRLOS, NSAIDs, RR
69  2000 How do we offer clinical relief to patients with gastro-oesophageal reflux disease? GORD, PPIs
70  2000 Management in peptic ulcer hemorrhage: a Dutch national inquiry. PPIs, PUH
71  2000 Peptic ulcer recurrence during maintenance therapy with H2-receptor antagonist following first-line therapy with proton pump inhibitor. DU, GU, PPI
72  2000 Proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. GERD, PPIs
73  2000 Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. NSAIDs
74  1999 Eradication of Helicobacter pylori does not decrease the long-term use of acid-suppressive medication. ---
75  1999 Medical therapy of gastroesophageal reflux disease in secondary and tertiary care settings. GERD, PPIs
76  1998 A prokinetic approach to treatment of gastroesophageal reflux disease. GERD, PPIs
77  1998 The Second Canadian Gastroesophageal Reflux Disease Consensus: moving forward to new concepts. GERD, PKs, PPIs
78  1998 Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients. PPIs
79  1997 Prevention of gastric ulcer relapse induced by indomethacin in rats by a mutein of basic fibroblast growth factor. bFGF
80  1997 Prokinetic therapy in gastroesophageal reflux disease. GERD
81  1996 Pharmacoeconomic analysis of stress ulcer prophylaxis for critically ill patients. AUGB
82  1996 Treatment of peptic ulcer in the elderly. Proton pump inhibitors and histamine H2 receptor antagonists. NSAID
83  1995 Intravenous histamine H2-receptor antagonists and parenteral nutrition: patterns of use. ---
84  1995 The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. GERD, GERD, PPIs
85  1992 Effect of histamine H2-receptor antagonists on vitamin B12 absorption. IF
86  1991 H2-receptor antagonist-refractory ulcer: its pathophysiology and treatment. PGE2
87  1991 Proton-pump inhibition for acid-related disease. ---
88  1991 Recent advances in the management of gastro-oesophageal reflux disease. ---
89  1990 Achieving pH control in the critically ill patient: the role of continuous infusion of H2-receptor antagonists. ICU
90  1990 Controlling gastric pH: the impact of newer agents on the critically ill patient. ---
91  1990 Hemodynamic effects of H2-receptor antagonists. ---
92  1990 Overview of the safety profile of the H2-receptor antagonists. ---
93  1990 Use of H2-receptor antagonists in children. ---